AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05132322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit & Feedback (real time, individual-level)
Description: Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
Study NCT05132322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit & Feedback (real time, individual-level)
Description: Real-time feedback will occur at the individual clinician level. When collecting data on an individual patient, data collectors encountering guideline-discordant continuous monitoring are empowered to briefly ask any available clinician responsible for that patient's care, in a nonjudgmental way, about indications for monitoring that patient. The clinician is ultimately responsible for deciding if any changes are indicated.
Study NCT05132322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Pathway Integrated into Electronic Health Record
Description: Clinical pathways guide clinicians step-by-step through evidence-based care. Based on the existing guidelines for physiologic monitoring in bronchiolitis, the pathway will clearly specify (a) situations when it is appropriate to initiate intermittent SpO2 measurement instead of continuous SpO2 monitoring, and (b) when it is appropriate to discontinue continuous SpO2 monitoring altogether, and transition to intermittent SpO2 measurement. In order to be visible to clinicians as they perform patient care, the pathway will be integrated into the electronic health record at sites randomized to this intervention.
Study NCT04841642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MANUAL THERAPY
Description: The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
Study NCT04841642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MANUAL THERAPY
Description: The investigators will apply manual therapy for ten minutes a week, for 8 weeks, based on cervical mobilizations and suboccipital inhibitions.
Study NCT04841642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THERAPEUTIC EXERCISE
Description: The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need.
Study NCT04841642 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THERAPEUTIC EXERCISE
Description: The exercises recommendations will be based on a simulation of the exercises in the same session of the manual therapy of each week, helped by the physiotherapist.~The access to telerehabilitation will be through a web page, through which patients could see explanatory videos of the exercises as many times as they need.
Study NCT05106699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton plus carbon ion radiation
Description: All patients received whole pelvis and prostate region proton irradiation of 46 GyE in 23 fractionsfollowed by localized carbon ion irradiation of 32GyE in 8 fractions to the prostate region. The dose to metastatic LN was escalated using simultaneous integrated boost (SIB) technique. The dose was 60-62.1GyE in 23 fractions as much as dose constraints. All patients will be recommened receive 2-3 years endocrine therapy.
Study NCT04660097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Description: This trial is single-armed IIb stage clinical trial to study the efficacy and safety of Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer . We use the outcome of CASPIAN trial as control group. The primary endpoint is ORR according to the RECIST 1.1, and secondary endpoints are PFS, OS, satety and life quality.
Study NCT05437497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Injection
Description: The experimental group was sedated with remimazolam
Study NCT05437497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: The control group was sedated with propofol
Study NCT05383222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technical task
Description: Simulated insertion of a central venous catheter
Study NCT05383222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administrative task
Description: Requesting a battery of investigations on the EPR
Study NCT06601101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin eye drops in the postoperative prescription for corneal crosslinking
Study NCT06601101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo eye drops of 0.5% Methylcellulose
Description: Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
Study NCT06667687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-291
Description: Intravenous Infusion
Study NCT06325592 — intervention group
Intervention type: PROCEDURE
Intervention: surgical timing and operation path
Description: surgical timing; laparoscopic hysterectomy or abdominal hysterectomy
Study NCT06278818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Telerehabilitation
Description: Cognitive training specifically designed to promote cognitive functions in early stages of neurodegenerative conditions.
Study NCT06278818 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Condition
Description: This activity is commonly used as a control condition to test the effectiveness of innovative rehabilitative treatments.
Study NCT04682405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Provided by study
Study NCT04682405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided by study
Study NCT04682405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: -Standard of care
Study NCT04682405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: -Standard of care
Study NCT05088707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
Study NCT05088707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic
Study NCT05896020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR- A1811
Description: Subjects with gynaecological malignancies
Study NCT05392348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stachyose
Description: Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1->6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
Study NCT05392348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.
Study NCT05396274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula
Description: high flow nasale cannula
Study NCT06434831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical device for SNM: Interstim II, Interstim micro
Description: ANI will be used during the SNM (2 hours)
Study NCT05500625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection
Description: Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
Study NCT05500625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ballon-occluded retrograde transvenous obliteration
Description: A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
Study NCT04994106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462, at dose levels of 1 to 5 in part A and at 1 to 4 in part B, respectively.
Study NCT06438510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Mucosal Ablation (GMA) of the fundus with Hybrid Argon Plasma Coagulation (HybridAPC) combined with Endoscopic Sleeve Gastroplasty (ESG)
Description: All endoscopic procedures will be performed with the patient in the supine position, under general anesthesia, with endotracheal intubation, in CO2 using a flexible endoscopic suturing system (OverStitchTM; Apollo Endosurgery, Austin, TX, USA) connected to a dual-channel endoscope (GIF-2TH180 or GIF-2TH160; Olympus, Center Valley, PA, USA ). The HybridAPC with submucosal injection and APC will be delivered by ErbeJet®2. ESG will be obtained by placing full-thickness sutures in the body gastric wall, from the angulus to the gastric fundus. Biopsy tissue will be collected from the gastric fundus and the samples will be fixed for histopathologic examination. In the next step HybridAPC to the gastric mucosa of the fundus is applied.
Study NCT05519540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant (Debio 1143)
Description: All participants (Japanese and non-Japanese East Asian) will receive single oral dose of xevinapant (Debio 1143) on Day 1.
Study NCT05857696 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: walking quantified analysis
Description: Test to measure anthropometry, joint amplitudes, muscle strength and spasticity of the lower limbs on a treadmill.
Study NCT05520554 — intervention group
Intervention type: OTHER
Intervention: Development of the Telerehabilitation Satisfaction Questionnaire
Description: This study will be examined the development, validity, and reliability of the Telerehabilitation Satisfaction Questionnaire in patients with MS.
Study NCT04375462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AspireAssist device
Description: Allows for aspiration of gastric contents into a receptacle or the toilet to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically in an identical fashion to a standard PEG tube G 1-2 days after enrollment
Study NCT04375462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard decompressive PEG tube
Description: Allows for gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration.~Device is placed endoscopically 1-2 days after enrollment
Study NCT04375462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastric outlet obstruction scoring system (GOOSS) questionnaire
Description: Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call
Study NCT04375462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gastric outlet obstruction scoring system (GOOSS) questionnaire
Description: Gastric outlet obstruction scoring system (GOOSS) questionnaire~Both groups will receive the questionnaires via a phone call
Study NCT04375462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire
Description: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call
Study NCT04375462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire
Description: Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire~Both groups will receive the questionnaires via a phone call
Study NCT04375462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient satisfaction and ease of use survey
Description: Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call
Study NCT04375462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient satisfaction and ease of use survey
Description: Patient satisfaction and ease of use survey~Both groups will receive the questionnaires via a phone call
Study NCT05989451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Description: The modified DBT protocol, developed by the principal investigator and co-investigators, will be offered in an individual therapy format. It consists of 12 weekly individual sessions, each lasting 50-60 minutes. It is made based on the manual, retaining the essence of DBT and remaining dialectically focused. Each session focuses on specific skills within the context of modules.
Study NCT05048524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin and gemcitabine
Description: Gemcitabine 800 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 1, S-1 orally 80-120 mg/day \[depending on patient's body surface area (BSA)\] on day 1 to 7 and leucovorin 30mg BID day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 80 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 100 mg/day~* BSA ≥ 1.5 m2: 120 mg/day
Study NCT05412602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full spine corrective protocol
Description: 36 chiropractic adjustments over 12 weeks (3 visits per week) with in office spinal traction on the 3D Denneroll Traction Table, as well as supplemental home exercises
Study NCT05618691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH312
Description: Oral tablet, GFH312 will be administered at 3 dose levels, each patient in one of three groups will be given a dose of 40mg, 80mg, 120mg of the study drug.
Study NCT05618691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered to subjects in the placebo group
Study NCT06134024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Introduction of double pigtail plastic stents through the LAMS during endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections
Description: During endoscopic procedure of endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces double pigtail plastic stents through the LAMS.
Study NCT06134024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections with use of LAMS only
Description: During endoscopic procedure of transmural drainage of post-inflammatory pancreatic and peripancreatic fluid collections the operator introduces transmurally the LAMS only, without the double pigtail plastic stents.
Study NCT06222788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Convertible Plasma Jet
Description: NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)
Study NCT04593264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-guided pre-habilitation exercise program
Description: A set of self-guided exercises developed by an athletic trainer to perform at home in order to optimize the knee for ACL repair surgery
Study NCT04593264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pre-habilitation
Description: Pre-habilitation exercise sessions under the direct supervision of a physical therapist.
Study NCT04497038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Patients will receive therapy with cabozantinib. Dosage in the trial will start at 40 mg PO daily. Each patient will be assessed for the development of toxicity according to the NCI Common Terminology Criteria for Adverse Events, version 5.0. Dose adjustments may be made per the Time-To-Event modification of the Continual Reassessment Method (TITE-CRM). The maximum dosage will be 60 mg PO daily and the minimum will be 20 mg PO daily.
Study NCT04724824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-Computer Interface
Description: Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis that will be activated by the brain-computer interface based on hand movement intention.
Study NCT04724824 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Brain-Computer Interface
Description: Passive hand movement will be provided to patients' paralyzed hand by means of a robotic hand orthosis which activation will be independent of the output of the brain-computer interface based on hand movement intention.
Study NCT04779788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)
Description: An I-125 seeds loaded stent consisted of two overlapped parts: an inner normal bare stent and an outer seeds-loaded stent
Study NCT04779788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)
Description: Bare self-expanded metal stent
Study NCT06492863 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FT-003
Description: Administered via intraocular injection.
Study NCT05260684 — intervention group
Intervention type: DRUG
Intervention: Encorafenib
Description: 450 mg QD
Study NCT05260684 — intervention group
Intervention type: DRUG
Intervention: Binimetinib
Description: 45 mg BID
Study NCT05260684 — intervention group
Intervention type: DRUG
Intervention: Vemurafenib
Description: 960 mg BID for 28 days/cycle
Study NCT05260684 — intervention group
Intervention type: DRUG
Intervention: Cobimetinib
Description: 60 mg QD for 21 days/cycle
Study NCT05260684 — intervention group
Intervention type: DRUG
Intervention: Dabrafenib
Description: 150 mg BID
Study NCT05260684 — intervention group
Intervention type: DRUG
Intervention: Trametinib
Description: 2 mg QD
Study NCT05068882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Oral immunonutrition containing arginine, omega-PUFAs and antioxidants
Study NCT05068882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-protein nutrition
Description: Oral nutrition with high-protein content
Study NCT05068882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutrition
Description: Oral nutrition with standard ingredients
Study NCT05865041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farudodstat
Description: Farudodstat tablets administered orally
Study NCT05865041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets administered orally
Study NCT06519695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercises
Description: Performed exercise three times a week, one time at a community health service station and two times at home
Study NCT04994106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo matched to AZD5462.
Study NCT06144099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fresh frozen plasma
Description: transfusion of fresh frozen plasma